Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Among authors: bernard s. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.
Management of aggressive lymphoma in very elderly patients.
Thieblemont C, Bernard S, Molina T. Thieblemont C, et al. Among authors: bernard s. Hematol Oncol. 2017 Jun;35 Suppl 1(Suppl Suppl 1):49-53. doi: 10.1002/hon.2413. Hematol Oncol. 2017. PMID: 28591412 Free PMC article. Review. No abstract available.
VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers.
Broséus J, Mourah S, Ramstein G, Bernard S, Mounier N, Cuccuini W, Gaulard P, Gisselbrecht C, Brière J, Houlgatte R, Thieblemont C. Broséus J, et al. Among authors: bernard s. Oncotarget. 2017 Jul 19;8(53):90808-90824. doi: 10.18632/oncotarget.19385. eCollection 2017 Oct 31. Oncotarget. 2017. PMID: 29207605 Free PMC article.
Optimizing initial therapy in DLBCL.
Thieblemont C, Bernard S, Meignan M, Molina T. Thieblemont C, et al. Among authors: bernard s. Best Pract Res Clin Haematol. 2018 Sep;31(3):199-208. doi: 10.1016/j.beha.2018.08.001. Epub 2018 Aug 7. Best Pract Res Clin Haematol. 2018. PMID: 30213389 Review.
L’arrivée de l’immunothérapie dans le lymphome de Hodgkin.
Gilardin L, Amorim S, Bernard S, Ravdan O, Thieblemont C, Brice P. Gilardin L, et al. Among authors: bernard s. Bull Cancer. 2018 Dec;105 Suppl 1:S50-S58. doi: 10.1016/S0007-4551(18)30390-4. Bull Cancer. 2018. PMID: 30595199 Review. French.
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study.
Lamure S, Duléry R, Di Blasi R, Chauchet A, Laureana C, Deau-Fischer B, Drenou B, Soussain C, Rossi C, Noël N, Choquet S, Bologna S, Joly B, Kohn M, Malak S, Fouquet G, Daguindau E, Bernard S, Thiéblemont C, Cartron G, Lacombe K, Besson C. Lamure S, et al. Among authors: bernard s. EClinicalMedicine. 2020 Oct;27:100549. doi: 10.1016/j.eclinm.2020.100549. Epub 2020 Oct 13. EClinicalMedicine. 2020. PMID: 33073216 Free PMC article.
1,417 results